Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer.

Trial Profile

Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2018

At a glance

  • Drugs Dutasteride (Primary) ; Bicalutamide; Goserelin; Ketoconazole; LHRH receptor agonists; Prednisone
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 26 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 09 Dec 2013 Results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top